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Animal(s): Female immunodeﬁcient BALB/c nude mice, 6 to 8 weeks old.
Intervention(s): Human fetal ovarian tissue slowly cryopreserved then subcutaneously transplanted in immunodeﬁcient mice.
Main OutcomeMeasure(s): Follicle survival assessed qualitatively and quantitatively using H&E staining, and cellular apoptosis of the
ovarian grafts evaluated using transmission electron microscopy and DNA nick end labeling in situ (TUNEL assay).
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VOL. 102 NO. 3 / SEPTEMBER 2014s progress has been achieved inA anticancer treatments, the curerate of cancer in children has
been greatly improved. Accordingly,
quality of life, especially with regard
to the preservation of fertility after can-
cer treatment, has become increasingly
important. The damage to fertility from
some anticancer therapies to ovaries is
irreversible. Alkylating agents, for
example, the most destructive among
all types of chemotherapy drugs, can
act on primordial follicles, decreasing
the ovarian reserve and resulting in
premature ovarian failure (1, 2).871
ORIGINAL ARTICLE: REPRODUCTIVE SCIENCETherefore, it is important to preserve the fertility of cancer
patients before initiating their anticancer treatments.
Cyclophosphamide (CTX) is one of themost frequently used
alkylating anticancer drugs.Although themechanisms underly-
inghowthedrug induces follicledamageare still unclear, studies
have demonstrated that follicle apoptosis occurs after the treat-
ment with CTX in cancer patients (2, 3), which indicates that it
may interfere with the cell decision of fate. A cell fate of
apoptosis or growth is related to the balance of ceramides and
sphingosine-1-phosphate (S1P). Ceramides suppress cell growth
and induce cell apoptosiswhereas S1Ppromotes cell growth and
mitosis (4, 5). Morita et al. (6) has demonstrated that
administration of S1P before radiotherapy prevents premature
ovarian failure in mice. In fact, S1P not only improved cell
proliferation but also suppressed cell death. In another study,
local administration of S1P in mouse ovaries decreased follicle
apoptosis and increased pregnancy rates in a dose-dependent
manner (7). The effect of S1P on CTX-treated human ovarian
follicle survival and development has yet to be reported.
Primordial follicles are formed as early as 13 weeks of
gestation in humans and become abundant from around 16
to 20 weeks of gestation (8, 9). Oocytes are arrested in the
diplotene stage of meiotic prophase I and are sensitive to
the local ovarian signals and metabolic requirements
provided by the surrounding granulosa cells. Cell death is
quantitatively a major activity of prenatal oocytes (10, 11).
At her time of birth, a woman's ovary has a ﬁnite reserve of
around 700,000 primordial follicles (12). After natural
depletion during fetal and postnatal development, these
primordial follicles constitute the reserve pool of germ cells
for the full duration of a woman's reproductive life span.
Premature ovarian failure results from the loss of the
primordial follicle pool in female ovaries.
Studies on the preservation of primordial follicles, using
fetal ovaries or adult ovaries, have important potential appli-
cations in the clinical treatment of cancer with antichemo-
therapy drugs. In our current study, we examined the
antiapoptosis effect of S1P on the survival and developmental
capacity of primordial follicles in cryopreserved human fetal
ovaries after the CTX treatment in a mouse xenograft mode.MATERIALS AND METHODS
Animals
Female immunodeﬁcient BALB/c Nudemice aged 6 to 8weeks
old were purchased from the SLAC animal laboratory in
Shanghai and were housed at the SPF facility of Animal Cen-
ter of Wenzhou Medical Collage, at a temperature of 23–25C
with a 12-hour light/dark cycle. Sterilized food and water
were available ad libitum. The animal experiments were re-
viewed and approved by the research ethics committee of
Wenzhou Medical College.Collection of Human Fetal Ovaries
With informed consent from the patients, fetal ovaries were
collected at autopsy from 10 aborted fetuses (23.9 1.4 weeks
of gestational age) within 3 hours. The human research ethics872committee of the First Afﬁliated Hospital of Wenzhou
Medical College approved the study.Reagents
We purchased S1P, Leibovitz (L-15), dimethyl sulfoxide
(DMSO), sucrose, ethanol, and sodium pentobarbital from
Sigma-Aldrich. The CTX was purchased from Jiangsu Heng
Rui Medicine, Ltd. Ethylene glycol (EG), fetal bovine serum
(FBS), TWEEN-80, and polyethylene glycol were purchased
from ZSBIO.Cryopreservation and Thawing of Human Fetal
Ovarian Tissue
Fetal ovaries were immersed in L-15 medium supplemented
with 10% FBS and transferred to the laboratory at 4C within
2 hours after collection. After dissecting the connective tissue,
the ovaries were cut into 3  3  3 mm cubes and placed in
cryovials (Greiner Bio-one) containing 1 mL of L-15 medium
supplemented with 1.5 M DMSO and 10% FBS for cryopreser-
vation, as previously described elsewhere (13). Brieﬂy, the
cryovials were loaded in a Planer Cryochamber (Planer PLC)
precooled to 0C. The vials were cooled at 2C/min to 7C
and held for 10 minutes, seeded manually, held at 7C for
a further 10 minutes, cooled to 40C at 0.3C/min, further
cooled to 140C at 10C/min, and ﬁnally transferred to
liquid nitrogen for storage. For thawing the ovarian tissue,
the cryovials were rapidly transferred to a water bath at
37C. The thawed tissues were washed in a serial process of
L-15 medium supplemented with 10% FBS and 0.25 M,
0.1 M, and 0 M sucrose for 10 minutes each.Xenotransplantation Procedure
The immunodeﬁcient nude mice were anesthetized by intra-
peritoneal injection of 100 mL of sodium pentobarbital diluted
1:4 in phosphate-buffered saline (PBS; Sigma-Aldrich). A
pocket was made between skin and muscle layer on back of
the mice through a dorsal-vertical incision. Frozen-thawed
ovarian tissue fragments were preincubated with either S1P,
PET (a solvent for S1P, consisting of 5% polyethylene glycol,
2.5% ethanol, and 0.8% TWEEN-80 in PBS), or PBS for 1 min-
ute at room temperature and then were inserted into the
pocket. We injected 5 mL of S1P, PET solvent, or PBS into
the pocket according to the pretreatment solution. Finally,
the skin incisions were closed with 7/0 silk sutures. The CTX
(10 mg/mL) was administrated to recipient mice by intraper-
itoneal injection at a dosage of 0.2 mg/g 1 hour after xeno-
transplantation. The ovarian grafts were retrieved 2 weeks
after grafting for evaluation. Two tissue fragments were
inserted into each pocket. A total of 30 tissue fragments
were grafted in the recipient nude mice.Experimental Design and Groups
Five groups (n ¼ 3 recipients in each group) were designed in
the experiments according to the solution that the ovarian tis-
suehadbeen treatedwith before grafting.GroupA: ovarian tis-
sue was preincubated with 2.0 mM S1P and grafted. Group B:VOL. 102 NO. 3 / SEPTEMBER 2014
Fertility and Sterility®ovarian tissue was preincubated with 0.5 mMS1P and grafted.
GroupC: ovarian tissuewas preincubatedwith PET solvent and
grafted. Group D: ovarian tissue was preincubated with PBS
and grafted. Group E: ovarian tissue was preincubated with
PBS and grafted, but the recipient mice were not injected
with CTX after xenotransplantation.Histology and Follicle Counting
Fresh and frozen-thawed ovarian tissue fragments and
ovarian grafts retrieved from the nude mice 2 weeks after
transplantation were ﬁxed in 4% paraformaldehyde over-
night at 4C, embedded in parafﬁn, serially sectioned at
5 mm, and stained with hematoxylin and eosin (H&E). Every
ﬁve sections were examined of each tissue block for the pres-
ence of primordial and primary follicles deﬁned according to
Gougeon (14). Brieﬂy, primordial follicles consist of one layer
of ﬂattened pregranulosa cells surrounding the oocytes and
primary follicles with one layer of cuboid granulosa cells.
To avoid counting follicles more than once, we counted the
follicles in the section where the dark-staining nucleolus
was seen within the nucleus of the oocytes, as previously
described elsewhere (15). Follicles were considered to be
abnormal according to the following characteristics: pyknosis
of granulosa cells, eosinophilia of ooplasms, and contraction/
clumping of oocyte chromatin materials; more 50% area of
the ooplasm occupied by vacuoles; or granulosa cells disor-
derly arranged and separated from the oocytes or the base
membrane around the follicles. The density of follicles was
expressed as the total number of follicles per high-power ﬁeld
(HPF, 400) under the microscope.DNA Nick End Labeling by In-situ TUNEL Staining
Ovarian graft tissue was processed histologically described as
earlier and mounted on SuperFrost Plus slides. Tissue sections
were deparafﬁnized by heating at 60C for 4 minutes and
washing twice in xylene for a total of 10minutes. The sections
were then rehydrated through a graded series of alcohols and
double distilled water. In-situ terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling (TUNEL)
assay was performed according the manufacturer's instruc-
tions (In Situ Cell Death Detection Kit; Roche). Fluorescein-
12-dUTP, once conjugated to the 30-OH ends of fragmented
DNA, stains the nuclei of apoptotic cells green. Tissue sections
were examined using a ﬂuorescence microscope (Fluoview
FV1000; Olympus). Cells were considered in apoptosis when
a positive signal was found in the oocyte, granulosa cell, or
stromal cell nuclei. The apoptosis index (AI) was calculated
as the number of apoptotic follicles divided by the total folli-
cle number.Transmission Electron Microscopy
Ovarian tissue fragments were cut into 1  1  1 mm cubes,
preﬁxedwith 1%osmium tetroxide for 1 hour at room temper-
ature, ﬁxed in 2.5% glutaraldehyde overnight at 4C, then de-
hydrated through a graded series of ethanol and 100%
acetone, and embedded in epoxy resin. Ultrathin sections
(120 nm) were cut and mounted on grids, and stained withVOL. 102 NO. 3 / SEPTEMBER 2014uranyl acetate and lead citrate for 5 minutes. The sections
were evaluated with an H-750 transmission electron micro-
scopy (TEM; Hitachi), as previously described elsewhere (16).Statistics
Quantitative results were expressed as mean standard error
of themean. The statistical signiﬁcance of differences between
means was evaluated using one-way analysis of variance
(ANOVA). P< .05 was considered statistically signiﬁcant.
RESULTS
Quantiﬁcation of Survival Primordial Follicles after
Cryopreservation
We ﬁrst examined the effect of the freezing-thawing proce-
dure on the survival of ovarian follicles in the human fetal
ovarian tissue. Human fetal ovaries at gestation age around
24 weeks contain only primordial follicles (Supplemental
Fig. 1A and B, available online). The primordial follicles
were well preserved after freezing-thawing procedure. The
density of primordial follicles in the frozen-thawed tissue
(n ¼ 3) was lower than that in the fresh tissue (n ¼ 3), but
the difference was not statistically signiﬁcant (P>.05)
(Supplemental Table 1, available online). The number of
normal follicles in the fresh and frozen-thawed tissue was
not statistically signiﬁcantly different (see Supplemental
Table 1).Quantiﬁcation of Survival Primordial/Primary
Follicles after Xenografting
All ovarian grafts were recovered 2 weeks after transplanta-
tion underneath the back skin of the recipient nude mice
(Supplemental Fig. 2A and B, available online). It was noted
that a very few primordial follicles developed to the primary
stage. Therefore, the number of follicles in each tissue block
was counted including primordial and primary follicles
(Table 1). The density of follicles and the number of normal
follicles in frozen-thawed ovarian grafts without CTX injec-
tion (group E, n ¼ 3) was statistically signiﬁcantly lower
than those in the ungrafted frozen-thawed ovarian tissue
(Fig. 1A), indicating that the transplantation procedure ac-
counted for a large loss of primordial follicles. Administration
of CTX in the recipient mice caused a statistically signiﬁcant
loss of follicles and increase in the number of abnormal folli-
cles in the ovarian grafts (groups B, C and D; Fig. 1B and C),
except in the ovarian grafts treated with 2.0 mM S1P (group
A, Fig. 1D). The density of the follicles and the number of
normal follicles in the grafts treated with a higher concentra-
tion of S1P (group A) were similar to those in frozen ovarian
grafts without CTX injection (group E).In Situ TUNEL Staining
A few scattered TUNEL-positive primordial oocytes or sur-
rounding stromal cells were present in the ovarian grafts
treated with 2.0 mM S1P in group A (Fig. 2A); there was no
statistically signiﬁcant difference compared with the ovarian
grafts without CTX exposure in group E (Table 1). A marked873
TABLE 1
The density of primordial/primary follicles, the number of normal and abnormal follicles per high-power ﬁeld and rate of apoptotic cells in ovarian
grafts among different experimental groups.
Group No. of primordial/primary follicles No. of normal follicles No. of abnormal follicles Rate of apoptotic cells (%)
A (CTX þ 2.0 mM S1P) 13.2  6.6a 8.0  3.9a 5.3  2.6a 18  2a
B (CTX þ 0.5 mM S1P) 9.8  5.2b 2.5  1.3b 7.3  3.9b 62  2b
C (CTX þ PET) 9.3  6.9b 1.9  1.4b 7.4  5.5b 68  3b
D (CTX þ PBS) 8.6  5.0b 1.6  0.9b 6.2  3.6b 71  4b
E (No CTX) 15.2  6.3a 9.9  4.1a 5.3  2.2a 15  3a
Note: Values with different superscript letters within the same column are signiﬁcantly different (P< .05). CTX ¼ cyclophosphamide; PET ¼ 5% polyethylene glycol, 2.5% ethanol, and 0.8%
TWEEN-80 in PBS; PBS ¼ phosphate-buffered saline; S1P ¼ sphingosine-1-phosphate.
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detected in ovarian grafts of groups B and C, especially of
group D (Fig. 2B–2D, Table 1). The distribution of apoptotic
cells showed that granulosa cells and stromal cells were
more prone to being affected by the CTX treatment than the
primordial oocytes.Ultrastructure
Frozen-thawed ovarian tissue (n¼ 3) and three ovarian grafts
in each experimental group (groups A–E) were observedFIGURE 1
Histological sections of grafted human fetal ovarian tissue with H&E stain
(experimental group A). (B) Ovarian graft exposed to CTX and treated wi
CTX and treated with PBS (experimental group D). (D) Ovarian graft wit
primordial follicles, arrowheads indicate the abnormal follicles. Bar ¼ 100
Meng. S1P suppresses apoptosis in ovarian tissue. Fertil Steril 2014.
874under TEM. Although vacuoles were detected in the cyto-
plasm of some oocytes, the majority of primordial follicles
in the frozen-thawed ovarian tissue displayed normal mito-
chondria, smooth nuclear membranes, and concentrated
chromatin in the nucleus of the oocytes (Fig. 3A and B).
Transplantation indeed caused ultrastructural abnormalities,
including swollen mitochondria (Fig. 3C), the disappearance
of cristae in mitochondria (Fig. 3D), and wrinkled nuclear
membranes (Fig. 3E). However, the 2.0 mM S1P treatment
of the grafts preserved the ultrastructures of the nuclear
membrane and mitochondria of the oocytes (Fig. 3F).ing. (A) Ovarian graft exposed to CTX and treated with 2.0 mM S1P
th 0.5 mM S1P (experimental group B). (C) Ovarian graft exposed to
hout CTX exposure (experimental group E). Arrows indicate normal
mm.
VOL. 102 NO. 3 / SEPTEMBER 2014
FIGURE 2
Representative sections of human fetal ovarian grafts processed for apoptosis using TUNEL staining. (A) CTX þ 0.5 mM S1P treated ovarian graft.
(B) CTX þ 2.0 mM S1P treated ovarian graft. (C) CTX þ PET treated ovarian graft. (D) CTX þ PBS treated ovarian graft. The greening staining
indicates TUNEL positive staining for DNA fragmentation. Bar ¼ 150 mm.
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In this study, the antiapoptotic effect of S1P on the survival of
primordial follicles in CTX-treated human fetal ovarian xeno-
grafts in nude mice was evaluated by follicle number count,
TEM, and apoptosis analysis. Alkylating agent CTX caused
a substantial follicle loss and apoptotic DNA fragmentation
in the ovarian grafts in a period of 2 weeks of transplantation.
Treatment of human fetal ovarian tissue with 2.0 mM S1P
signiﬁcantly maintained the primordial follicle population
in the grafts exposed to CTX, with results similar to the grafts
without CTX exposure. Ovarian grafts treated with 2.0 mM
S1P also showed that signiﬁcantly few TUNEL-positive cells
were observed. In accordance with these observations,
2.0 mM S1P treatment preserved the ultrastructures of the
nuclear membrane and mitochondria integrity of the oocytes
in the grafts.
As more advanced anticancer treatments, including
chemotherapy, are applied to patients, some of these treat-
ments destroy the ovarian reserve, leading to premature
ovarian failure (5, 17, 18). Ovarian tissue cryopreservation
and transplantation have been proved to be successful
strategies for restoring fertility to cancer-survival patients
(16, 19, 20), although these transplantation procedures still
need to be optimized (21, 22). Our current study conﬁrmed
the observation that a major loss of follicles occurs after
grating rather than the freeze-thaw procedure.
Apoptosis is one of the mechanisms responsible for folli-
cle loss (17, 23). Using an apoptosis suppression factor such as
S1P, which induces cell growth and proliferation, has beenVOL. 102 NO. 3 / SEPTEMBER 2014suggested as a potential means of protecting ovarian
follicles from chemotherapy damage (5, 24). S1P is the
ligand for a family of G protein-coupled receptors. Five types
of S1P receptor have been cloned: s1p1 (EDG-1), s1p2 (EDG-
5), s1p3 (EDG-3), s1p4 (EDG-6), and s1p5 (EDG-8). Its biolog-
ical functions are related to the type of receptor because
different G proteins act as downstream second messengers,
but the exact mechanism is not yet known (5, 25).
Protective effects of S1P on mice ovaries when given
chemotherapy and radiotherapy have been reported (25),
and an initial study reported on the local administration of
S1P on the survival of primordial follicles in human ovarian
grafts using a xenotransplantation model in nude mice (26).
Selection for survival or cell death of oocytes within the
ovary occurs at all stages of oocyte development. Before birth,
a largemajority of oocytes are lost in the fetal ovary. Frombirth
to puberty, the ovarian reserve reduces from around 700,000 to
300,000 primordial follicles. During adulthood, the process of
selection of the ovulating follicles is competitive. About
1,000 follicles are destined for atresia, with only one or two
destined for ovulation during a menstrual cycle. Moreover,
oocyte atresia can happen at any stage of follicular develop-
ment from primordial to preovulatory stage (27). This high
baseline of apoptosis level may mask the effects of S1P treat-
ment, so a set of proper control groups is critical in such studies.
Cyclophosphamide (CTX), a frequently used chemo-
therapy drug, damages human ovaries at an administration
of 0.2 mg/g (21, 28–30). We demonstrated that follicle loss,
abnormal ultrastructure, and apoptosis occur in xenografted875
FIGURE 3
Transmission electron microscopy. (A, B) Frozen-thawed ovarian tissue. Arrow indicates a vacuole in the cytoplasm and arrowhead indicates a
normal mitochondrion. (C) CTX þ 0.5 mM S1P treated ovarian graft. Arrows indicate swollen mitochondria in cytoplasm. (D) CTX þ PBS
treated ovarian graft. Arrows indicate the abnormal mitochondria with disappeared cristae. (E) Ovarian graft without CTX exposure. Arrows
indicate normal mitochondria. (F) CTX þ 2.0 mM S1P treated ovarian graft. Arrows indicate normal mitochondria.
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mechanisms by which chemotherapy destroys primordial
follicles are directed toxicity via induction of apoptosis in
the pregranulosa cells and the oocytes, and indirect damage
to ovarian stromal cells (31). Evidence of stromal damage in
human ovarian tissue has been found from women exposed
to a variety of chemotherapy regimes that include CTX.
Stromal damage in these patients is characterized by
vascular damage and cortical ﬁbrosis (23). Although its
cytotoxicity is not cell cycle-dependent, CTX does have an876increased effect on proliferating cells such as granulosa and
stromal cells in growing follicles (32). Dormant primordial
follicles in human ovarian tissue fragments exposed to CTX
and then xenotransplanted to immunodeﬁcient mice showed
positive staining for apoptosis in our study and those of others
(33). A newly suggested mechanism is that CTX activates the
growth of the quiescent primordial follicle population, which
results in a ‘‘burnout’’ effect and follicle depletion (34).
Our study showed that S1P can suppress CTX-induced
follicle apoptosis at concentration of 2.0 mM but not at aVOL. 102 NO. 3 / SEPTEMBER 2014
Fertility and Sterility®low concentration of 0.5 mM. Further studies are required to
optimize the dosage for treatments and to investigate the
mechanism of its antiapoptotic function. We have shown
that S1P can protect primordial follicles in human fetal
ovarian grafts from alkylating-agent CTX-exposure damage
via suppressing follicle apoptosis. The developmental capac-
ity of the primordial follicle thus protected from chemo-
therapy damage by S1P still needs further investigation.
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SUPPLEMENTAL FIGURE 1
Histologic sections of human fetal ovarian tissue with H&E staining. (A) Fresh human fetal ovarian tissue. (B) Frozen-thawed human fetal ovarian
tissue. Arrows indicate primordial follicles. Bar ¼ 100 mm.
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SUPPLEMENTAL FIGURE 2
Transplantation of human fetal ovarian tissue. (A) Xenografting of human fetal ovarian tissue beneath the back skin of the nude mice (arrow).
(B) The ovarian grafts (arrows) were revascularized and recovered 2 weeks after transplantation. Bar ¼ 5 mm.
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SUPPLEMENTAL TABLE 1
The density of primordial follicles, the number of normal and
abnormal follicle per high-power ﬁeld under microscope in fresh
and frozen-thawed human 24-week fetal ovarian tissue.
Group
No. of primordial
follicles
No. of normal
follicles
No. of abnormal
follicles
Fresh 25  14.8 23.2  14.8 1.8  1.0
Frozen-thawed 24.8  14.4 21.8  12.6 2.0  1.7
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